Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05965206
Status:
RECRUITING
Last Update Posted:
2023-07-28
First Post:
2023-07-20
Brief Title:
Implementation of a Pharmacist-Based Post-Chemotherapy Follow-up Clinic
Sponsor:
Cedars-Sinai Medical Center
Organization:
Cedars-Sinai Medical Center
Study Overview
Official Title:
Implementation of a Pharmacist-Based Post-Chemotherapy Follow-up Clinic
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the impact of pharmacists on reducing chemotherapy-related side effects by providing education before and after patients receive intravenous chemotherapy at one of Cedars-Sinai outpatient infusion centers
Participants will be interviewed via telephone within 7 business days after receiving intravenous chemotherapy from the outpatient cancer center infusion clinic
Participants will be interviewed via telephone within 7 business days after receiving intravenous chemotherapy from the outpatient cancer center infusion clinic
Detailed Description:
The study involves participation at a single timepoint only
Participants who consented to participate and are considered eligible will be interviewed by a pharmacist via phone at approximately 7 business days after receiving intravenous chemotherapy infusion Phone call will be made between the hours of 9am - 6pm on Monday - Saturday Calls are anticipated to last between 15 to 20 minutes Participants will be asked if they have experienced any adverse events since the infusion whether or not they have had any barriers taking supportive care medications and if the patient understands how to manage potential adverse events If applicable participants will be provided further education on optimizing adverse events guided on proper medication administration times and will be provided with non-pharmacological clinical pearls to minimize chemotherapy-related side effects and optimize supportive care management
If unable to reach the participant or caregiver after three attempts the participant will be considered ineligible Participants can decline participation at any time during the phone call
Participants who consented to participate and are considered eligible will be interviewed by a pharmacist via phone at approximately 7 business days after receiving intravenous chemotherapy infusion Phone call will be made between the hours of 9am - 6pm on Monday - Saturday Calls are anticipated to last between 15 to 20 minutes Participants will be asked if they have experienced any adverse events since the infusion whether or not they have had any barriers taking supportive care medications and if the patient understands how to manage potential adverse events If applicable participants will be provided further education on optimizing adverse events guided on proper medication administration times and will be provided with non-pharmacological clinical pearls to minimize chemotherapy-related side effects and optimize supportive care management
If unable to reach the participant or caregiver after three attempts the participant will be considered ineligible Participants can decline participation at any time during the phone call
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None